Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial.

Objectives: We sought to demonstrate the safety and performance of the actinomycin D-coated Multilink-Tetra stent(Guidant Corp., Santa Clara, California) in the treatment of patients with single de novo native coronary lesions.

Background: Drug-eluting stents (DES) releasing sirolimus or paclitaxel dramatically reduce restenosis.